Skip to main content
Premium Trial:

Request an Annual Quote

VisEn, Merck to Co-Develop Fluorescence Agents for Biomarker Imaging

NEW YORK (GenomeWeb News) — VisEn Medical and Merck & Co. plan to develop and apply fluorescence agents to image disease-related biomarkers in vivo, VisEn said today.
Merck aims to integrate the companies’ technologies to develop drug candidates and to “establish new standards for the identification and assessment of disease,” said Richard Hargreaves, Merck’s vice president of imaging.
VisEn said the program will use proprietary and literature-derived biomarkers linked to cardiovascular disease together with VisEn’s fluorescence agents and fluorescence molecular tomography imaging systems.
The agents will be used in in vivo imaging tools to track how diseases progress and show a therapeutic response.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.